7 February 2023


Neuro-Bio is a privately-owned UK biotech company out of Oxford University. Its unique value proposition is based on its identification of the pivotal mechanism leading to the neurodegeneration that characterises Alzheimer’s disease.

Neuro-Bio is working on the development of a preventative pre-symptomatic treatment for Alzheimer’s and a complementary pre-symptomatic test for the disease (in the form of a lateral flow test).

The pre-symptomatic test offers the possibility of detecting neurodegeneration in the 10-20 years before Alzheimer’s symptoms present. If the company’s treatment was then available, it could be given before any memory loss was apparent, halt the progressive cycle of cell death, and thus prevent any cognitive impairment.

Read more